Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia

NCT07516561 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 336

Last updated 2026-04-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.

Conditions

  • Alopecia, Androgenetic

Interventions

DRUG

APSMNF 1

Administer twice a day during 24 weeks.

DRUG

APSMNF 2

Administer twice a day during 24 weeks.

DRUG

Eniagor®

Administer twice a day during 24 weeks.

Sponsors & Collaborators

  • Apsen Farmaceutica S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-07
Primary Completion
2029-08-02
Completion
2029-08-02

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07516561 on ClinicalTrials.gov